This antibody can be used for the study of muscles and their development, including studies of myogenesis. This particular antibody recognises skeletal muscle tropomyosin
| Inventor | Institute |
|---|---|
| Gurtej Dhoot | University of Birmingham |
| Cat. #: | 151607 |
|---|---|
| Unit size: | 100 ug |
| Research Fields: | Cell biology |
| Application: | WB |
| Target: | Human Skeletal Muscle Tropomyosin |
| Reactivity: | Human ; Mouse ; Rat |
| Clone: | Tropomyosin |
| Host: | Sheep |
| Class: | Polyclonal |
| Product description: | This antibody can be used for the study of muscles and their development, including studies of myogenesis. This particular antibody recognises skeletal muscle tropomyosin |
|---|---|
| Conjugation: | Unconjugated |
| Immunogen: | Whole skeletal muscle tropomyosin |
| Target background: | This antibody can be used for the study of muscles and their development, including studies of myogenesis. This particular antibody recognises skeletal muscle tropomyosin |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -20° C |
| Shipping conditions: | Dry ice |
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151025 | Anti-Vascular endothelium [10] |
Key Info
Anti-Vascular endothelium [10]
|
View Tool | |||||||||||||||||||
| 151027 | Anti-HSVICP8 [10A3] |
Key Info
Anti-HSVICP8 [10A3]
|
View Tool | |||||||||||||||||||
| 151031 | Anti-RuvA [RuvA 12C6] |
Key Info
Anti-RuvA [RuvA 12C6]
|
View Tool | |||||||||||||||||||
| 151034 | Anti-HSVUL42 [13D11] |
Key Info
Anti-HSVUL42 [13D11]
|
View Tool | |||||||||||||||||||
| 151036 | Anti-ICAM1 [15.2] |
Key Info
Anti-ICAM1 [15.2]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.